Test Price
2,800 AED✅ Home Collection Available
ABCC8 Gene Hyperinsulinemic Hypoglycemia Type 1 Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
Accuracy: 99.9% diagnostic sensitivity via ISO-accredited Next-Generation Sequencing (NGS).
Price: 2,800 AED — all-inclusive, no hidden fees.
Turnaround: 3–4 weeks from sample receipt to final report.
Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test interpretation session included with a board-certified genetic counselor.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ABCC8 gene genetic test detects pathogenic variants causing congenital hyperinsulinemic hypoglycemia type 1 (familial hyperinsulinism) through comprehensive coding-region analysis using Next-Generation Sequencing. This test provides definitive molecular diagnosis for patients with persistent hypoglycemia, differentiates diffuse from focal disease, and guides targeted treatment planning including surgical intervention when indicated.
| Feature | Our Test (ABCC8 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision / Coverage | Full gene coding region, deep NGS (99.9% analytical sensitivity) | Targeted exons only; limited detection of deep intronic variants |
| Methodology | Next-Generation Sequencing (NGS) | Chain-termination (Sanger) sequencing |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
Physician Insight & Safety Protocols
A Note from Lina Osama Zaki Quteineh, Consultant Medical Genetics — DHA Registration ID: 9294403:
"This test is a critical diagnostic tool for identifying pathogenic variants in the ABCC8 gene that cause congenital hyperinsulinemic hypoglycemia. Results must be interpreted within the full clinical context, including metabolic profiles and family history. A negative result does not exclude all genetic causes of hyperinsulinism, while a positive result can enable precise, targeted management. Patients should never discontinue prescribed glucose-raising therapies or diazoxide without explicit instruction from their treating endocrinologist."
Medication Advisory
Medication Warning
Do not discontinue prescribed medication, especially glucose-raising therapies or diazoxide, without explicit medical advice from your endocrinologist. Abrupt cessation can precipitate severe hypoglycemia requiring emergency intervention.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- This test is not intended for emergency diagnosis of acute hypoglycemia. If the patient experiences seizures, loss of consciousness, or a blood glucose reading below 40 mg/dL (2.2 mmol/L), seek immediate emergency care.
- Asymptomatic individuals without a confirmed family history of hyperinsulinism should undergo genetic counseling before testing.
- Testing of minors requires explicit parental or guardian consent and a formal genetic counseling session, in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the ABCC8 gene test and why is it recommended?
The ABCC8 gene test identifies pathogenic variants that cause congenital hyperinsulinemic hypoglycemia type 1, a condition marked by persistent low blood sugar due to excess insulin secretion. This test provides a definitive molecular diagnosis, distinguishes diffuse from focal disease, and guides treatment decisions including medication management and potential surgical intervention. It also enables family risk assessment and reproductive planning.
2. How is the test performed and what sample is required?
The test requires a single blood draw of 1 mL whole blood or a dried blood spot on an FTA card. Samples can be collected at our accredited facility or through our VIP Mobile Phlebotomy service with temperature-controlled cold-chain transport, available daily from 8 AM to 11 PM. No fasting or medication adjustment is needed unless specifically directed by your doctor.
3. What is the turnaround time and how will I receive my results?
Results are available within 3–4 weeks from sample receipt. You will receive your report securely through our clinic portal, and a board-certified genetic counselor will contact you for a telephonic interpretation session to explain the findings, their implications, and recommended next steps. Copies can be provided to your treating endocrinologist upon request.
4. Does insurance cover this test?
We offer direct billing verification for most UAE insurance plans. Please send a WhatsApp message to +971 54 548 8731 with your policy details to confirm coverage and any applicable co-payment or deductible before scheduling your sample collection.
5. What does a positive or negative result mean for my treatment?
A positive result confirms a pathogenic variant in the ABCC8 gene and can guide targeted therapies such as diazoxide or surgical intervention for focal disease. A negative result reduces the likelihood of ABCC8-related hyperinsulinism but does not exclude other genetic causes. All results must be interpreted by your endocrinologist in the context of your full clinical picture and family history.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This genetic testing service is provided in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is encrypted, access-controlled, and processed solely for diagnostic purposes with explicit consent. All clinical procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient safety and informed consent throughout the testing pathway.
Clinical & Logistical Metadata
| Test Name | ABCC8 Gene Hyperinsulinemic Hypoglycemia Type 1 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (1 mL) or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) — Full Coding Region Analysis |
| ICD-10-CM Code | E16.1, Z13.79, Z84.89 |
| LOINC Code | 97920-5 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians